1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Cardiomyopathies in 5 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merkus, D | 1 |
| Tune, JD | 1 |
| Mishra, RK | 1 |
| Alokam, R | 1 |
| Sriram, D | 1 |
| Yogeeswari, P | 1 |
| Wang, N | 1 |
| Guan, P | 1 |
| Zhang, JP | 1 |
| Chang, YZ | 1 |
| Gu, LJ | 1 |
| Hao, FK | 1 |
| Shi, ZH | 1 |
| Wang, FY | 1 |
| Chu, L | 1 |
| Guo, P | 1 |
| Wu, C | 1 |
| Masaki, T | 1 |
| Mori, H | 1 |
| Nishiyama, A | 1 |
| Satoh, Si | 1 |
| Ikegaki, I | 1 |
| Toshima, Y | 1 |
| Watanabe, A | 1 |
| Asano, T | 1 |
| Shimokawa, H | 1 |
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cardiomyopathies
| Article | Year |
|---|---|
Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomyopathies; Diabetes Complicat | 2013 |
4 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cardiomyopathies
| Article | Year |
|---|---|
ROCK as a molecular bond connecting coronary microvascular and cardiac remodelling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Cardiomyopathies; Endothelin-1; Humans; Hypertrophy; | 2017 |
Preventive effects of fasudil on adriamycin-induced cardiomyopathy: possible involvement of inhibition of RhoA/ROCK pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; bcl-2-Associated X Protein; Cardiomyopathies | 2011 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomyopathies; Chronic Disease; Disease M | 2002 |